Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Fukang (Shanghai) Health Technology

Request full access

Researcher and developer of innovative drugs focused on oncology treatments

ChinaFounded 2015Biotech & Life Sciences

About Fukang (Shanghai) Health Technology

Convalife (Shanghai) Health Technology Co., Ltd., operating as Convalife Pharmaceuticals, is a clinical-stage biopharmaceutical company established in 2015 with a focus on developing treatments for oncology, virology, and age-related diseases. The company was founded by Dr. Xiaokun Shen, who also serves as the chairman and CEO. Convalife operates with a global perspective, maintaining its headquarters in Shanghai and additional offices in Guangzhou and Boston.

The company's business model centers on the research and development of original drugs with "First-in-Class" or "Best-in-Class" potential to address unmet medical needs worldwide. Convalife has a robust pipeline that includes small molecule drugs and bispecific antibodies. Key products in development include CVL218, a second-generation PARP inhibitor, and CVL237, a highly selective PI3K β/δ dual inhibitor. The company's portfolio targets a range of cancers such as breast, lung, prostate, and pancreatic cancer, as well as various infectious diseases like COVID-19 and Respiratory Syncytial Virus (RSV). Revenue generation is driven by strategic partnerships, licensing agreements, and venture capital funding. The company has successfully raised significant capital through multiple funding rounds, including a Series C in January 2024 for $14 million.

Convalife has established numerous strategic collaborations to advance its pipeline. In August 2024, it partnered with Shanghai Henlius Biotech, granting them exclusive rights to commercialize neratinib (HANNAIJIA) in China for HER2-positive breast cancer treatment. This drug was approved by China's NMPA in June 2024. Another significant agreement was made in July 2022, when Convalife acquired the global rights for the PI3K β/δ inhibitor CVL-237 from Karus Therapeutics Ltd. The company also collaborates with other major entities like Hutchmed (China) Ltd. and Wuxi Biologics for combination therapies and development support, respectively.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.0/100
Industry
Health
Sub-industry
Pharmaceutical
Sector
Biotechnology, Oncology, Spinout, Biotech and Pharma, DT and LS, science-based
Links
Website

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES C✓Equity / VC Jan 2024 $14M $55M Xicheng Zhiyuan ↗
SPINOUT✓Other financing Jan 2015 $0 — Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences —
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Fukang (Shanghai) Health Technology website traffic

Latest recorded traffic for Fukang (Shanghai) Health Technology is 180 monthly website visits, up 20% over the last three months.

Latest monthly visits180 3-month web change+20%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Fukang (Shanghai) Health Technology in its local ecosystem

Live from Dealroom

The Fukang (Shanghai) Health Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

2 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series B and later1 investor entered at this stage

  • Xicheng Zhiyuan

Other known investors1 additional known investor

  • Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Fukang (Shanghai) Health Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Fukang (Shanghai) Health Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.